Exicure (NYSE:XCUR) Announces Quarterly Earnings Results

Exicure (NYSE:XCUR) issued its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, reports. The company had revenue of $0.53 million during the quarter.

Shares of XCUR stock opened at $2.49 on Friday. Exicure has a one year low of $1.62 and a one year high of $4.20.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Exicure in a research report on Wednesday.

Exicure Company Profile

Exicure, Inc, a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis.

See Also: Why do corrections happen?

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.